{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:00:30Z","timestamp":1781647230914,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop an Arg-Gly-Asp peptide (RGD)-targeted hollow mesoporous manganese dioxide nanoparticle system loaded with cisplatin (RGD-HMnO\u2082\/CDDP) and evaluate its in vitro antitumor activity, in vivo therapeutic efficacy, and mechanisms in colon cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Hollow MnO\u2082 (HMnO\u2082) was fabricated using SiO\u2082 nanospheres as a hard template via KMnO\u2084 oxidative deposition followed by Na\u2082CO\u2083 etching. Cisplatin was loaded and RGD peptides were conjugated to obtain RGD-HMnO\u2082\/CDDP. Morphology and physicochemical properties were characterized by TEM, XRD, XPS, DLS, and zeta potential. In CT26 cells, cytotoxicity (CCK-8), invasion\/migration (Transwell), reactive oxygen species (ROS, DCFH-DA), mitochondrial membrane potential (JC-1), DNA damage (\u03b3-H2AX), apoptosis (Western blot; Annexin V-FITC\/PI) were assessed. In tumor-bearing mice, antitumor efficacy, serum cytokines (TNF-\u03b1, IFN-\u03b3, IL-6, IL-2, IL-10), and hematological indices were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>RGD-HMnO\u2082\/CDDP showed markedly enhanced cytotoxicity versus free cisplatin and non-targeted HMnO\u2082\/CDDP, and significantly inhibited invasion and migration. Mechanistically, it increased intracellular ROS, induced mitochondrial depolarization, elevated \u03b3-H2AX, and activated apoptosis signaling, resulting in higher apoptotic rates. In vivo, RGD-HMnO\u2082\/CDDP achieved superior tumor growth inhibition, modulated inflammatory\/immune cytokines, and maintained favorable hematological profiles, indicating good immunomodulation and biocompatibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RGD-HMnO\u2082\/CDDP enhances cisplatin efficacy against colon cancer by promoting ROS-driven mitochondrial dysfunction and DNA damage\u2013associated apoptosis, with potential improvement of the tumor immune microenvironment and without compromising systemic safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15923-5","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:47:16Z","timestamp":1775908036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RGD-modified hollow mesoporous nanoparticles loaded with cisplatin for antitumor therapy in colon cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaohou","family":"Xi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"3","key":"15923_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15923_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10207","key":"15923_CR3","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer[J]. Lancet. 2019;394(10207):1467\u201380.","journal-title":"Lancet"},{"issue":"8","key":"15923_CR4","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol. 2016;27(8):1386\u2013422.","journal-title":"Ann Oncol"},{"issue":"3","key":"15923_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson 3rd","year":"2021","unstructured":"Benson AB 3rd, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2021[J]. J Natl Compr Canc Netw. 2021;19(3):329\u201359.","journal-title":"J Natl Compr Canc Netw"},{"issue":"23","key":"15923_CR6","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability\u2013High Advanced Colorectal Cancer[J]. N Engl J Med. 2020;383(23):2207\u201318.","journal-title":"N Engl J Med"},{"issue":"8","key":"15923_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L. The resurgence of platinum-based cancer chemotherapy[J]. Nat Rev Cancer. 2007;7(8):573\u201384.","journal-title":"Nat Rev Cancer"},{"key":"15923_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action[J]. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"issue":"15","key":"15923_CR9","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance[J]. Oncogene. 2012;31(15):1869\u201383.","journal-title":"Oncogene"},{"issue":"19","key":"15923_CR10","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1039\/C8DT00838H","volume":"47","author":"R Oun","year":"2018","unstructured":"Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: A review for chemists[J]. Dalton Trans. 2018;47(19):6645\u201353.","journal-title":"Dalton Trans"},{"issue":"1","key":"15923_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41581-022-00631-7","volume":"19","author":"C Tang","year":"2023","unstructured":"Tang C, Livingston MJ, Safirstein R, Dong Z. Cisplatin nephrotoxicity: New insights and therapeutic implications[J]. Nat Rev Nephrol. 2023;19(1):53\u201372.","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"15923_CR12","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.3390\/cancers14122904","volume":"14","author":"MU Munir","year":"2022","unstructured":"Munir MU. Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue[J]. Cancers. 2022;14(12):2904.","journal-title":"Cancers"},{"issue":"12","key":"15923_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","volume":"2","author":"D Peer","year":"2007","unstructured":"Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy[J]. Nat Nanotechnol. 2007;2(12):751\u201360.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"15923_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges and opportunities[J]. Nat Rev Cancer. 2017;17(1):20\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"15923_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery[J]. Nat Biotechnol. 2015;33(9):941\u201351.","journal-title":"Nat Biotechnol"},{"key":"15923_CR16","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours[J]. Nat Rev Mater. 2016;1:16014.","journal-title":"Nat Rev Mater"},{"issue":"11","key":"15923_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","volume":"14","author":"R van der Meel","year":"2019","unstructured":"van der Meel R, Sulheim E, Shi Y, et al. Smart cancer nanomedicine[J]. Nat Nanotechnol. 2019;14(11):1007\u201317.","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"15923_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery[J]. Nat Rev Drug Discov. 2021;20(2):101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"15923_CR19","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1038\/s41388-023-02869-2","volume":"42","author":"P Fan","year":"2023","unstructured":"Fan P, Zhang N, Candi E, et al. Alleviating hypoxia to improve cancer immunotherapy[J]. Oncogene. 2023;42:3591\u2013604.","journal-title":"Oncogene"},{"issue":"6","key":"15923_CR20","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.21147\/j.issn.1000-9604.2025.06.11","volume":"37","author":"P Zhang","year":"2025","unstructured":"Zhang P, Liang X, Ye B, et al. Metabolic reprogramming signature predicts immunotherapy efficacy in lung adenocarcinoma: Targeting SLC25A1 to overcome immune resistance[J]. Chin J Cancer Res. 2025;37(6):1000\u201319.","journal-title":"Chin J Cancer Res"},{"issue":"11","key":"15923_CR21","doi-asserted-by":"publisher","first-page":"e18408","DOI":"10.1111\/jcmm.18408","volume":"28","author":"P Zhang","year":"2024","unstructured":"Zhang P, Yang Z, Liu Z, et al. Deciphering lung adenocarcinoma evolution: Integrative single-cell genomics identifies the prognostic lung progression associated signature[J]. J Cell Mol Med. 2024;28(11):e18408.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"15923_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41746-025-02172-2","volume":"8","author":"Z Gong","year":"2025","unstructured":"Gong Z, Du M, Li Y, et al. Machine learning identifies TIME subtypes linking EGFR mutations and immune states in lung adenocarcinoma[J]. NPJ Digit Med. 2025;8(1):796.","journal-title":"NPJ Digit Med"},{"key":"15923_CR23","doi-asserted-by":"publisher","first-page":"849040","DOI":"10.3389\/fgene.2022.849040","volume":"13","author":"A Sharma","year":"2022","unstructured":"Sharma A, Sinha S, Shrivastava N. Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism[J]. Front Genet. 2022;13:849040.","journal-title":"Front Genet"},{"issue":"7","key":"15923_CR24","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.3390\/cancers13071711","volume":"13","author":"BS Ludwig","year":"2021","unstructured":"Ludwig BS, Kessler H, Kossatz S, Reuning U. RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field[J]. Cancers. 2021;13(7):1711.","journal-title":"Cancers"},{"key":"15923_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12964-023-01264-4","volume":"21","author":"S Li","year":"2023","unstructured":"Li S, Sampson C, Liu C, et al. Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities[J]. Cell Commun Signal. 2023;21:266.","journal-title":"Cell Commun Signal"},{"issue":"11","key":"15923_CR26","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3390\/ph17111556","volume":"17","author":"S Lopes","year":"2024","unstructured":"Lopes S, Silva N, Arrieta C, P\u00eago AP. Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine\u2013Glycine\u2013Aspartate) Strategies[J]. Pharmaceuticals. 2024;17(11):1556.","journal-title":"Pharmaceuticals"},{"key":"15923_CR27","doi-asserted-by":"publisher","first-page":"1477409","DOI":"10.3389\/fphar.2024.1477409","volume":"15","author":"B Wang","year":"2024","unstructured":"Wang B, Tang D, Cui J, et al. RGD-based self-assembling nanodrugs for improved tumor therapy[J]. Front Pharmacol. 2024;15:1477409.","journal-title":"Front Pharmacol"},{"key":"15923_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40580-024-00456-z","volume":"11","author":"SG Balwe","year":"2024","unstructured":"Balwe SG, Moon D, Hong M, Song JM. Manganese oxide nanomaterials: Bridging synthesis and therapeutic innovations for cancer treatment[J]. Nano Convergence. 2024;11:48.","journal-title":"Nano Convergence"},{"issue":"2","key":"15923_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1039\/C8NH00274F","volume":"4","author":"J Chen","year":"2019","unstructured":"Chen J, Meng H, Tian Y, et al. Recent advances in functionalized MnO\u2082 nanosheets for biosensing and biomedical applications[J]. Nanoscale Horiz. 2019;4(2):321\u201338.","journal-title":"Nanoscale Horiz"},{"issue":"52","key":"15923_CR30","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1039\/D0CC02782K","volume":"56","author":"J Wen","year":"2020","unstructured":"Wen J, Yang K, Sun S. MnO\u2082-Based nanosystems for cancer therapy[J]. Chem Commun (Camb). 2020;56(52):7065\u201379.","journal-title":"Chem Commun (Camb)"},{"key":"15923_CR31","doi-asserted-by":"publisher","first-page":"12455","DOI":"10.1039\/D3NR01976D","volume":"15","author":"QQ Wang","year":"2023","unstructured":"Wang QQ, Liu J, He LC, et al. Nanozyme: a rising star for cancer therapy[J]. Nanoscale. 2023;15:12455\u201363.","journal-title":"Nanoscale"},{"key":"15923_CR32","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1039\/D3NR05592B","volume":"16","author":"Y Ye","year":"2024","unstructured":"Ye Y, Zou J, Wu W, et al. Advanced nanozymes possess peroxidase-like catalytic activities in biomedical and antibacterial fields: review and progress[J]. Nanoscale. 2024;16:3324\u201346.","journal-title":"Nanoscale"},{"key":"15923_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, et al. Immunogenic cell stress and death[J]. Nat Immunol. 2022;23:487\u2013500.","journal-title":"Nat Immunol"},{"issue":"5","key":"15923_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.trecan.2023.02.001","volume":"9","author":"K H\u00e4nggi","year":"2023","unstructured":"H\u00e4nggi K, Ruffell B. Cell death, therapeutics, and the immune response in cancer[J]. Trends Cancer. 2023;9(5):381\u201396.","journal-title":"Trends Cancer"},{"issue":"9","key":"15923_CR35","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41556-024-01429-4","volume":"26","author":"HL Glover","year":"2024","unstructured":"Glover HL, Schreiner A, Dewson G, et al. Mitochondria and cell death[J]. Nat Cell Biol. 2024;26(9):1434\u201346.","journal-title":"Nat Cell Biol"},{"key":"15923_CR36","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","volume":"24","author":"PE Czabotar","year":"2023","unstructured":"Czabotar PE, Garcia-Saez AJ. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis[J]. Nat Rev Mol Cell Biol. 2023;24:732\u201348.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"15923_CR37","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41418-023-01153-w","volume":"30","author":"I Vitale","year":"2023","unstructured":"Vitale I, Pietrocola F, Guilbaud E, et al. Apoptotic cell death in disease: current understanding of the NCCD 2023[J]. Cell Death Differ. 2023;30(5):1097\u2013154.","journal-title":"Cell Death Differ"},{"issue":"3","key":"15923_CR38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018[J]. Cell Death Differ. 2018;25(3):486\u2013541.","journal-title":"Cell Death Differ"},{"key":"15923_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10989-023-10523-4","volume":"29","author":"L Yin","year":"2023","unstructured":"Yin L, Li X, Wang R, et al. Recent Research Progress of RGD Peptide\u2013Modified Nanodrug Delivery Systems in Tumor Therapy[J]. Int J Pept Res Ther. 2023;29:53.","journal-title":"Int J Pept Res Ther"},{"key":"15923_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12951-023-01850-1","volume":"21","author":"F Pi","year":"2023","unstructured":"Pi F, Deng X, Xue Q, et al. Alleviating the hypoxic tumor microenvironment with MnO\u2082-coated CeO\u2082 nanoplatform for magnetic resonance imaging guided radiotherapy[J]. J Nanobiotechnol. 2023;21:90.","journal-title":"J Nanobiotechnol"},{"key":"15923_CR41","doi-asserted-by":"publisher","first-page":"215027","DOI":"10.1016\/j.ccr.2023.215027","volume":"480","author":"H Fan","year":"2023","unstructured":"Fan H, Guo Z. Tumor microenvironment-responsive manganese-based nanomaterials for cancer treatment[J]. Coord Chem Rev. 2023;480:215027.","journal-title":"Coord Chem Rev"},{"key":"15923_CR42","doi-asserted-by":"publisher","first-page":"17218","DOI":"10.1039\/D1NR05512G","volume":"13","author":"M Jiang","year":"2021","unstructured":"Jiang M, Zeng J, Zhao L, et al. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo\u2013immunotherapy[J]. Nanoscale. 2021;13:17218\u201335.","journal-title":"Nanoscale"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15923-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:50:42Z","timestamp":1781646642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15923-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15923"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15923-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"642"}}